import image1 from '@/assets/news/20220802_1.jpg'

export default {
  en: {
    title: 'SynOV1.1 was administered to the first patient in the Phase I clinical trial in China',
    abstract: 'On August 2, 2022, SyngenTech announced that SynOV1.1 was administered to the first patient in the Phase I clinical trial in China.',
    cover: image1,
    content: `
  <div style="text-align:center"><img src="${image1}"></img></div>
  <p>On August 2, 2022, SyngenTech Co., LTD. (Hereinafter referred to as SyngenTech) announced that SynOV1.1, the company's first oncolytic virus gene therapy product for the treatment of advanced liver cancer, was administered to the first patient in the Phase I clinical trial in China. The core technology of SynOV1.1 product is derived from the long-term close cooperation between SyngenTech and Tsinghua University. It is the first oncolytic virus engineered by using synthetic gene circuits in the world. This phase I clinical trial aims to evaluate the safety, tolerability and antitumor activity of SynOV1.1 single agent intra-tumoral injection in patients with advanced liver cancer.</p>
  <p>The principal investigators of the clinical trial, Professor Lu Guoye and Professor Ding Yanhua of the First Hospital of Jilin University, pointed out that: "SynOV1.1 uses synthetic gene circuit to identify multiple biomarkers in liver cancer cells, including alpha-fetoprotein promoter and microRNAs, which can accurately identify tumor cells and improve the killing effect. Compared with other products under research, there are certain potential advantages. We expect SynOV1.1 to demonstrate its antitumor efficacy in clinical trial and provide new treatment options for cancer patients."</p>
    `
  },
  zh: {
    title: 'SynOV 1.1 中国一期临床研究完成首例受试者给药',
    abstract: '2022年8月2日，合生基因第一款用于治疗晚期肝癌的溶瘤病毒产品 SynOV1.1 腺病毒注射液，完成了中国一期临床研究的首例受试者给药',
    cover: image1,
    content: `
  <div style="text-align:center"><img src="${image1}"></img></div>
  <p>2022年8月2日，北京合生基因科技有限公司宣布，公司第一款用于治疗晚期肝癌的溶瘤病毒产品SynOV1.1腺病毒注射液，完成了中国一期临床研究的首例受试者给药。SynOV1.1产品的核心技术源于合生基因与清华大学的长期紧密合作，是国际上首款采用合成生物技术设计构建的溶瘤病毒产品。本次一期临床研究旨在评价 SynOV1.1单药瘤内注射在晚期肝癌患者中的安全性、耐受性和抗肿瘤活性等。</p>
  <p>该项临床研究的主要研究者、吉林大学第一医院吕国悦书记和丁艳华教授指出：“SynOV1.1利用人工基因线路设计可以识别肝癌细胞内包括甲胎蛋白启动子、microRNA等多个生物标志物，能够精准识别肿瘤和提高杀伤效果。相对目前其他在研产品，存在一定潜在优势。我们期待SynOV1.1在临床研究中发挥抗肿瘤疗效，为肿瘤病人提供新的治疗选择。</p>
    `
  }
}
